Pascale Witz Net Worth

The estimated Net Worth of Pascale Witz is at least $2.89 Millón dollars as of 28 April 2023. Ms. Witz owns over 3,913 units of Horizon Therapeutics Plc stock worth over $2,116,893 and over the last 7 years she sold HZNP stock worth over $279,035. In addition, she makes $494,608 as Independent Director at Horizon Therapeutics Plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Witz HZNP stock SEC Form 4 insiders trading

Pascale has made over 8 trades of the Horizon Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently she exercised 3,913 units of HZNP stock worth $455,082 on 28 April 2023.

The largest trade she's ever made was buying 29,630 units of Horizon Therapeutics Plc stock on 7 May 2019 worth over $32,000. On average, Pascale trades about 2,046 units every 44 days since 2017. As of 28 April 2023 she still owns at least 18,202 units of Horizon Therapeutics Plc stock.

You can see the complete history of Ms. Witz stock trades at the bottom of the page.

Pascale Witz biography

Pascale Witz is Independent Director of the Company. Ms. Witz founded PWH Advisors, a strategic consultancy firm advising healthcare and investment companies, in November 2016 and has served as its president since that time. From September 2015 to May 2016, Ms. Witz served as executive vice president, global diabetes and cardiovascular at Sanofi, a pharmaceutical company, hich she joined in July 2013 as executive vice president, pharma and CHC divisions. During her tenure at Sanofi, she launched multiple medicines across three continents and strengthened the pipeline through licensing and partnerships. Prior to Sanofi, Ms. Witz served more than 17 years at GE Healthcare where, in her final role as president and chief executive officer of its pharmaceutical diagnostics business, she ran a $2 billion integrated pharmaceutical organization that encompassed research and development through commercialization. Ms. Witz also serves on the boards of directors of Fresenius Medical Care AG & Co. KGaA, a public medical supply company, Regulus Therapeutics Inc., a public biotechnology company, PerkinElmer, Inc., a public company focused on human and environmental health, PWH Advisors, Capsule Technologies Inc., a private medical technology company and Arkuda Therapeutics, Inc., a private biopharma company.

What is the salary of Pascale Witz?

As the Independent Director of Horizon Therapeutics Plc, the total compensation of Pascale Witz at Horizon Therapeutics Plc is $494,608. There are 13 executives at Horizon Therapeutics Plc getting paid more, with Timothy Walbert having the highest compensation of $13,873,200.

How old is Pascale Witz?

Pascale Witz is 53, she's been the Independent Director of Horizon Therapeutics Plc since 2017. There are 14 older and 9 younger executives at Horizon Therapeutics Plc. The oldest executive at Horizon Therapeutics Plc is William Daniel, 67, who is the Independent Director.

What's Pascale Witz's mailing address?

Pascale's mailing address filed with the SEC is C/O REGULUS THERAPEUTICS INC., 4224 CAMPUS POINT COURT #210, SAN DIEGO, CA, 92121.

Insiders trading at Horizon Therapeutics Plc

Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over $454,905,275 worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth $58,823,653 . The most active insiders traders include Jeff Himawan, Woodlands Health Ventures F... y Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of $12,248,018. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth $351,691.

What does Horizon Therapeutics Plc do?

at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.

Complete history of Ms. Witz stock trades at Horizon Therapeutics Plc, Regulus Therapeutics Inc y Revvity

Horizon Therapeutics Plc executives and stock owners

Horizon Therapeutics Plc executives and other stock owners filed with the SEC include:

• Timothy Walbert,
  Chairman of the Board, President, Chief Executive Officer
• Timothy P. Walbert,
  Chairman, Pres & CEO
• Barry Moze,
  Executive Vice President, Chief Administrative Officer
• Paul Hoelscher,
  Chief Financial Officer, Executive Vice President
• Vikram Karnani,
  Executive Vice President, President - International
• Paul W. Hoelscher,
  Exec. VP & CFO
• Andy Pasternak,
  Exec. VP & Chief Strategy Officer
• Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D.,
  Exec. VP & Chief Medical Officer
• Michael Grey,
  Lead Independent Director
• Jeffrey Himawan,
  Independent Director
• H. Thomas Watkins,
  Independent Director
• James Shannon,
  Independent Director
• William Daniel,
  Independent Director
• Pascale Witz,
  Independent Director
• Susan Mahony,
  Independent Director
• Irina Konstantinovsky,
  Chief Human Resource Officer, Executive Vice President
• Daniel Camardo,
  Executive Vice President, President - U.S.
• Jeffrey Kent,
  Senior Vice President, Head of Medical Affairs and Outcomes Research
• Andy Pasternak,
  Executive Vice President, Chief Business Officer
• Geoffrey Curtis,
  Executive Vice President - Corporate Affairs, Chief Communications Officer
• Tina Ventura,
  Senior Vice President, Investor Relations
• Michael DesJardin,
  Executive Vice President - Technical Operations and Corporate Quality
• Brian Beeler,
  Executive Vice President, General Counsel
• Aaron L. Cox,
  Exec. VP of Fin. & CFO
• Jane Gonnerman,
  Group VP of Corp. Devel., Chief of Staff & Office of the CEO
• Geoffrey M. Curtis,
  Exec. VP of Corp. Affairs & Chief Communications Officer
• Sean M. Clayton J.D.,
  Exec. VP & Gen. Counsel
• Timothy Ayers,
  Chief Compliance Officer & VP
• Dr. Karin Rosen M.D., Ph.D.,
  Exec. VP of R&D and Chief Scientific Officer
• Miles W. McHugh,
  Chief Accounting Officer & Sr. VP
• Robert Carey,
  EVP & Chief Business Officer
• Jeff Himawan,
  Director
• Gino Santini,
  Director
• Timothy J. Ackerman,
  SVP, Commercial Operations
• Miles W Mc Hugh,
  Sr VP & Princ. Acctg Officer
• George P Hampton,
  See remarks
• Virinder Nohria,
  Director
• Ronald Pauli,
  Director
• Vaere Robert J De,
  EVP & CFO
• Therapeutics Holdings Llc V...,
  10% owner
• Todd N Smith,
  SVP, Marketing & Alliance Mgmt
• David Happel,
  EVP, Commercial Dev & Strategy
• Eric Mosbrooker,
  SVP, Orphan Business Unit
• Shao Lee Lin,
  EVP, Head of R&D and CSO
• Jeff Kent,
  See remarks
• Jeffrey W Bird,
  Director
• Michael Adatto,
  Senior VP Sales & Managed Care
• Bio Ventures Ii Lp Quaker,
  10% owner
• Venture Fund Vi Lp Atlas Ve...,
  
• Peter Johann,
  Director
• Jean Francois Formela,
  Director
• Venture Fund Vi Lp Atlas Ve...,
  
• Woodlands Health Ventures F...,
  10% owner
• Louis C Bock,
  Director
• Hubert Birner,
  Director
• John B Thomas,
  EVP, Corporate Strategy and IR
• David George Kelly,
  EVP, Company Secretary
• John J Kody,
  EVP, Chief Commercial Officer
• Balaji Venkataraman,
  
• Aaron Cox,
  EVP, Chief Financial Officer
• Jeffrey W Sherman,
  EVP and Chief Medical Officer
• Karin Rosen,
  EVP, R&D & CSO
• Elizabeth H.Z. Thompson,
  EVP, Research & Development
• Sean M. Clayton,
  EVP, General Counsel
• Jacopo Leonardi,
  Pres., Global Commercial Ops
• Patrick Mc Ilvenny,
  Chief Accounting Officer